Arvinas Operations Inc. has reported the development of diacylglycerol kinase α (DGK-α; DGKA) inhibitors reported to be useful for the treatment of cancer.
Research at Vanderbilt University has led to the identification of new muscarinic M5 receptor antagonists reported to be useful for the treatment of psychiatric disorders.
Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, diabetes type 2, obesity and metabolic diseases.
C4x Discovery Holdings plc has prepared and tested mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors. As such, they are reported to be useful for the treatment of cancer, asthma, gout and psoriasis, among others.
Cryptosporidiosis is a parasitic infection caused by Cryptosporidium where infected individuals develop profuse watery diarrhea and enteric symptoms such as abdominal pain. In immunocompromised or malnourished children, the infection may become chronic and lead to significant morbidity and mortality rates.
Viral proteases are well-established therapeutic targets in HIV and hepatitis C virus infections. Following the recent COVID-19 pandemic, one of the strategies in place is SARS-CoV-2 main protease (Mpro) inhibition, given the crucial role of SARS-CoV-2 Mpro in the replication of the virus.
Investigators from Beatson Institute for Cancer Research have published findings from a study that applied untargeted metabolic profiling to identify novel therapeutic targets for colorectal cancer (CRC). Genetically engineered mouse models and multimodal mass spectrometry-based metabolomics were used to analyze metabolic effects of common genetic mutations in CRC.
Hanchorbio Inc. and Shanghai Henlius Biotech Inc. have entered into a strategic framework agreement for collaboration to combine Hanchorbio’s protein engineering expertise and proprietary Fc-based designer biologics (FBDB) technology platform with Henlius’ integrated product development and commercialization capabilities.
RSS
